According to our recent payer coverage analysis for psoriatic arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for psoriatic arthritis treatments shows that under the pharmacy benefit, about 70% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In September 2020, the FDA expanded the use of the Janssen Pharmaceutical Companies of Johnson & Johnson’s Simponi Aria (golimumab) for people at least 2 years of age for the treatment of active polyarticular juvenile idiopathic arthritis and expanded the active psoriatic arthritis indication to the same patient population.